Volume 26, Number 11—November 2020
Research
Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China
Table 2
Proportion of isolates demonstrating antimicrobial resistance in systematic review and meta-analyses of incidence of group B Streptococcus disease in infants, China*
Reference |
Publication year |
No. isolates |
PEN |
AMP |
CFZ |
CAX |
VAN |
LZD |
CHL |
ERY |
TET |
CIP |
MXF |
LVX |
NIT |
TGC |
Zeng et al. | 2013 | 11 | 0 | 0 | NT | NT | 0 | 0 | NT | NT | 100.0 | 9.1 | 9.1 | 9.1 | 0 | 0 |
Luo et al. | 2013 | 15 | 0 | 0 | NT | 0 | 0 | NT | NT | 86.7 | NT | NT | NT | 0 | NT | NT |
Zheng et al. | 2014 | 12 | 0 | 0 | NT | NT | 0 | NT | NT | 16.7 | 66.7 | NT | NT | NT | NT | NT |
Chen et al. | 2014 | 16 | 0 | 0 | NT | 0 | 0 | NT | NT | 62.5 | NT | 25.0 | NT | 18.8 | NT | NT |
Zhu et al. | 2014 | 13 | 0 | 10.0 | 0 | 100.0 | 38.5 | 0 | 100.0 | 100.0 | NT | 33.3 | NT | 8.3 | 0 | NT |
Fan et al. | 2014 | 42 | 0 | 0 | NT | NT | 0 | 0 | NT | 69.1 | 73.8 | NT | NT | 38.1 | NT | 0 |
Wang et al. | 2015 | 15 | 0 | 20.0 | 40.0 | 80.0 | 0 | 0 | 86.7 | 100.0 | NT | 26.7 | NT | 20.0 | 0 | NT |
Zhang et al. | 2015 | 6 | 0 | 0 | 83.3 | NT | 0 | 0 | NT | NT | NT | NT | NT | NT | NT | NT |
Lei et al. | 2015 | 20 | NT | 0 | NT | NT | 0 | 0 | 25.0 | 75.0 | NT | 80.0 | NT | 70.0 | 0 | NT |
Zhang et al. | 2015 | 45 | 0 | 2.2 | NT | NT | 0 | 0 | NT | 42.2 | 93.3 | 0 | 0 | 0 | NT | 0 |
Cai et al. | 2016 | 15 | 0 | 0 | NT | NT | 0 | 0 | NT | 46.7 | 100.0 | NT | 6.7 | 6.7 | 13.3 | 0 |
Zhao | 2016 | 28 | 0 | 0 | NT | 0 | 0 | 3.6 | NT | 67.9 | NT | NT | NT | 42.9 | NT | NT |
Huang et al. | 2016 | 49 | NT | NT | NT | NT | NT | NT | NT | 63.3 | 98.0 | 11.9 | 12.2 | 7.7 | NT | NT |
Liu et al. | 2017 | 15 | 0 | NT | NT | NT | 0 | NT | NT | NT | NT | NT | NT | NT | NT | NT |
Zhang et al. | 2017 | 55 | 0 | 0 | NT | NT | 0 | 0 | NT | 56.6 | 98.1 | 1.9 | NT | NT | NT | NT |
Zhang et al. | 2017 | 15 | 6.7 | 0 | NT | NT | 0 | 0 | NT | NT | 80.0 | 73.3 | 73.3 | 60.0 | 0 | 0 |
Tan et al. | 2017 | 20 | 0 | 0 | NT | NT | 0 | 0 | NT | NT | 100.0 | 16.7 | NT | 16.7 | NT | 0 |
Zhou et al. | 2017 | 84 | 4.8 | 2.4 | 2.4 | 0 | 0 | 0 | 4.8 | 72.6 | 100.0 | 35.2 | NT | 36.9 | 0 | NT |
Zhao | 2017 | 45 | 0 | NT | NT | 0 | 0 | 2.2 | NT | 64.4 | NT | NT | NT | 42.2 | NT | NT |
Guan et al. | 2018 | 68 | 0 | NT | NT | 0 | 0 | 0 | NT | 57.4 | 95.6 | NT | NT | 5.9 | NT | NT |
Median | NA | NA | 0 | 0 | 21.2 | 0 | 0 | 0 | 55.8 | 64.4 | 98.0 | 25.0 | 9.1 | 17.7 | 0 | 0 |
IQI 25% | NA | NA | 0 | 0 | 0.6 | 0 | 0 | 0 | 9.8 | 56.6 | 80.0 | 9.1 | 3.3 | 6.9 | 0 | 0 |
IQI 75% | NA | NA | 0 | 1.7 | 72.5 | 60.0 | 0 | 0 | 96.7 | 75.0 | 100 | 35.2 | 42.8 | 41.2 | 0 | 0 |
*Values are percentages. Reference details are provided in the Appendix (https://wwwnc.cdc.gov/EID/26/11/18-1414-App1.pdf). Green indicates a rate of AMR <25%; yellow 25%–50%; red >50%; 25%, and 75% refers to AMR interquartile interval of 25% and 75%. Amp, ampicillin; CFZ, cefazolin; CAX, ceftriaxone, CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; IQI, interquartile interval; LZD, linezolid; MXF, moxifloxacin; NA, not applicable; NIT, nitrofurantoin; NT, not tested; PEN, penicillin: TET, tetracycline; TGC, tigecycline; VAN, vancomycin.